Cargando…

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation

(1) Background: Niraparib and Talazoparib are poly (ADP-ribose) polymerase (PARP) 1/2 inhibitors. It is assumed that combining PARP inhibitors with radiotherapy could be beneficial for cancer treatment. In this study, melanoma cells were treated with Niraparib and Talazoparib in combination with ion...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jonuscheit, Stephanie, Jost, Tina, Gajdošová, Fritzi, Wrobel, Maximilian, Hecht, Markus, Fietkau, Rainer, Distel, Luitpold
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229922/ https://www.ncbi.nlm.nih.gov/pubmed/34073147 http://dx.doi.org/10.3390/genes12060849

Ejemplares similares

PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts
por: Weigert, Verena, et al.
Publicado: (2020)

Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells
por: Dobler, Clara, et al.
Publicado: (2020)

Influence of alectinib and crizotinib on ionizing radiation - in vitro analysis of ALK/ROS1-wildtype lung tissue cells
por: Jost, Tina, et al.
Publicado: (2022)

Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation
por: Jost, Tina, et al.
Publicado: (2021)

Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential
por: Bürkel, Felix, et al.
Publicado: (2020)

Kinase Inhibitors of DNA-PK, ATM and ATR in Combination with Ionizing Radiation Can Increase Tumor Cell Death in HNSCC Cells While Sparing Normal Tissue Cells
por: Faulhaber, Eva-Maria, et al.
Publicado: (2021)

Kinase inhibitors increase individual radiation sensitivity in normal cells of cancer patients
por: Jost, Tina, et al.
Publicado: (2022)

Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation
por: Hecht, Markus, et al.
Publicado: (2018)

Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts
por: Scheper, Julian, et al.
Publicado: (2022)

The Effect of Xevinapant Combined with Ionizing Radiation on HNSCC and Normal Tissue Cells and the Impact of Xevinapant on Its Targeted Proteins cIAP1 and XIAP
por: Fleischmann, Julia, et al.
Publicado: (2023)

Deterioration of Health-Related Quality of Life Scores under Treatment Predicts Longer Survival
por: Jörling, Maike, et al.
Publicado: (2020)

Effect of Citrate- and Gold-Stabilized Superparamagnetic Iron Oxide Nanoparticles on Head and Neck Tumor Cell Lines during Combination Therapy with Ionizing Radiation
por: Schreiber, Christoph, et al.
Publicado: (2022)

Differences in and Prognostic Value of Quality of Life Data in Rectal Cancer Patients with and without Distant Metastases
por: Frank, Fabian, et al.
Publicado: (2020)

Ex Vivo Apoptosis in CD8+ Lymphocytes Predicts Rectal Cancer Patient Outcome
por: Winkler, Sebastian, et al.
Publicado: (2016)

Baseline Quality of Life of Physical Function Is Highly Relevant for Overall Survival in Advanced Rectal Cancer
por: Fitz, Tim, et al.
Publicado: (2022)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
por: Lakomy, David S., et al.
Publicado: (2019)

Increase in non-professional phagocytosis during the progression of cell cycle
por: Hofmann, Alexander, et al.
Publicado: (2021)

Role of tumor cell senescence in non-professional phagocytosis and cell-in-cell structure formation
por: Gottwald, Dorian, et al.
Publicado: (2020)

CD8+ and Regulatory T cells Differentiate Tumor Immune Phenotypes and Predict Survival in Locally Advanced Head and Neck Cancer
por: Echarti, Alessia, et al.
Publicado: (2019)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
por: Zhou, Dong, et al.
Publicado: (2021)

Cell-in-cell phenomenon: leukocyte engulfment by non-tumorigenic cells and cancer cell lines
por: Bauer, Mareike F., et al.
Publicado: (2021)

Rate of individuals with clearly increased radiosensitivity rise with age both in healthy individuals and in cancer patients
por: Schuster, Barbara, et al.
Publicado: (2018)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Influence of Gender on Radiosensitivity during Radiochemotherapy of Advanced Rectal Cancer
por: Schuster, Barbara, et al.
Publicado: (2021)

Non-Professional Phagocytosis Increases in Melanoma Cells and Tissues with Increasing E-Cadherin Expression
por: Unseld, Luzie Helene, et al.
Publicado: (2023)

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
por: Herriott, Ashleigh, et al.
Publicado: (2015)

Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells
por: Hecht, Markus, et al.
Publicado: (2015)

A case of niraparib PARP-Inhibitor induced Sweet Syndrome in gynecologic cancer
por: Badiner, Nora, et al.
Publicado: (2023)

Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation
por: Lesueur, Paul, et al.
Publicado: (2018)

Cell-in-cell structures are more potent predictors of outcome than senescence or apoptosis in head and neck squamous cell carcinomas
por: Schenker, Hannah, et al.
Publicado: (2017)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

Increased Radiation Sensitivity in Patients with Phelan-McDermid Syndrome
por: Jesse, Sarah, et al.
Publicado: (2023)

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
por: Yap, Timothy A., et al.
Publicado: (2022)

Regulatory T cells and cytotoxic T cells close to the epithelial–stromal interface are associated with a favorable prognosis
por: Rudolf, Julian, et al.
Publicado: (2020)

In Vitro Analysis of Superparamagnetic Iron Oxide Nanoparticles Coated with APTES as Possible Radiosensitizers for HNSCC Cells
por: Emer, Clara, et al.
Publicado: (2023)

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
por: Shen, Hong-Yuan, et al.
Publicado: (2022)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m7n7e4sdr3lifu819p7lagh180